Wongkaewkhiaw, Saharut

Loading...
Thumbnail Image
Preferred name
Wongkaewkhiaw, Saharut
Main Affiliation
Email
saharut.wo@kmitl.ac.th

Settings

Now showing 1 - 2 of 2
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
    Cymbopogon citratus L. essential oil as a potential anti-biofilm agent active against antibiotic-resistant bacteria isolated from chronic rhinosinusitis patients
    (2024-01-01)
    Khosakueng, Mintra
    ;
    Taweechaisupapong, Suwimol
    ;
    Boonyanugomol, Wongwarut
    ;
    Prapatpong, Pornpan
    ;
    Wongkaewkhiaw, Saharut
    Chronic rhinosinusitis (CRS) is long-term inflammation of the sinuses that can be caused by infection due to antibiotic-resistant bacteria. Biofilm developed by microbes is postulated to cause antibiotic treatment failure. Thus, the anti-biofilm activities of seven Thai herbal essential oils (EOs) against antibiotic-resistant bacteria isolated from CRS patients was investigated. Lemongrass (Cymbopogon citratus L.) EO showed the most effective antibiofilm activity against Klebsiella pneumoniae, Pseudomonas aeruginosa and Staphylococcus epidermidis grown as biofilm. GC-MS analysis found that myrcene was the major bioactive compound. Pretreatment with lemongrass EO significantly inhibited biofilm formation of all bacterial strains in more than 50% of cases. Furthermore, confocal microscopy analysis revealed the biofilm-disrupting activity of lemongrass EO against the biofilm matrix of all these bacterial species and also increased P. aeruginosa swarming motility with no toxicity to human cells. These results suggest that lemongrass EO has promising clinical applications as an anti-biofilm agent for CRS patients.
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
    Vitamin D (1α,25(OH)2D3) supplementation minimized multinucleated giant cells formation and inflammatory response during Burkholderia pseudomallei infection in human lung epithelial cells
    (2023-02-01)
    Mattrasongkram, Pohnratchada
    ;
    Wongkaewkhiaw, Saharut
    ;
    Taweechaisupapong, Suwimol
    ;
    Chareonsudjai, Sorujsiri
    ;
    Techawiwattanaboon, Teerasit
    Melioidosis is an infectious disease with high mortality rates in human, caused by the bacterium Burkholderia pseudomallei. As an intracellular pathogen, B. pseudomallei can escape from the phagosome and induce multinucleated giant cells (MNGCs) formation resulting in antibiotic resistance and immune evasion. A novel strategy to modulate host response against B. pseudomallei pathogenesis is required. In this study, an active metabolite of vitamin D<inf>3</inf> (1α,25-dihydroxyvitamin D<inf>3</inf> or 1α,25(OH)<inf>2</inf>D<inf>3</inf>) was selected to interrupt pathogenesis of B. pseudomallei in a human lung epithelium cell line, A549. The results demonstrated that pretreatment with 10<sup>−6</sup> M 1α,25(OH)<inf>2</inf>D<inf>3</inf> could reduce B. pseudomallei internalization to A549 cells at 4 h post infection (P < 0.05). Interestingly, the presence of 1α,25(OH)<inf>2</inf>D<inf>3</inf> gradually reduced MNGC formation at 8, 10 and 12 h compared to that of the untreated cells (P < 0.05). Furthermore, pretreatment with 10<sup>−6</sup> M 1α,25(OH)<inf>2</inf>D<inf>3</inf> considerably increased hCAP-18/LL-37 mRNA expression (P < 0.001). Additionally, pro-inflammatory cytokines, including MIF, PAI-1, IL-18, CXCL1, CXCL12 and IL-8, were statistically decreased (P < 0.05) in 10<sup>−6</sup> M 1α,25(OH)<inf>2</inf>D<inf>3</inf>-pretreated A549 cells by 12 h post-infection. Taken together, this study indicates that pretreatment with 10<sup>−6</sup> M 1α,25(OH)<inf>2</inf>D<inf>3</inf> has the potential to reduce the internalization of B. pseudomallei into host cells, decrease MNGC formation and modulate host response during B. pseudomallei infection by minimizing the excessive inflammatory response. Therefore, 1α,25(OH)<inf>2</inf>D<inf>3</inf> supplement may provide an effective supportive treatment for melioidosis patients to combat B. pseudomallei infection and reduce inflammation in these patients.